MENU
ABBV
Stock ticker: NYSE
PRICE
CHANGE
CAPITALIZATION

ABBV stock forecast, quote, news & analysis

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta)... Show more

A.I.Advisor
published price charts
A.I.Advisor
Nov 07, 2026

AbbVie (ABBV) Stock Analysis: Skyrizi and Rinvoq Power the Post-Humira Growth Era

Key Takeaways

  • AbbVie shares have advanced roughly 7% over the past month, supported by a third-quarter earnings beat and an upward revision to full-year guidance.
  • Third-quarter 2026 revenue rose about 10% to $17.4 billion, while adjusted earnings per share of $3.82 exceeded the company's guidance midpoint.
  • Skyrizi and Rinvoq, the company's newer immunology medicines, each grew more than 20% and are more than offsetting Humira's biosimilar-driven decline.
  • Management raised full-year revenue guidance to approximately $67.8 billion and adjusted EPS guidance to $13.95–$13.99.
  • AbbVie announced a 5.2% dividend increase to $1.82 per share, reinforcing its reputation as a dividend-growth name.
  • For deeper data, explore AbbVie's Price Targets, Earnings, and Forecast pages.
  • Discover how automated strategies are positioned across the market by exploring Trending AI Robots.

Current Market Snapshot

AbbVie Inc. (ABBV) has traded with a modestly positive bias over the trailing month, with shares rising from the low-$270s in early October to roughly $291 in recent sessions. The advance has been driven primarily by a strong third-quarter earnings report and an accompanying lift in full-year guidance, rather than by a single outsized catalyst. Broader sentiment toward large-cap pharmaceuticals has remained constructive, and AbbVie's combination of double-digit revenue growth in key franchises plus a growing dividend has kept the stock in focus for both growth- and income-oriented investors.

AbbVie (ABBV) Business Overview and Competitive Position

AbbVie is a global, research-based biopharmaceutical company that discovers, develops, and commercializes innovative therapies across four core areas: immunology, oncology, neuroscience, and aesthetics. Its flagship growth drivers are Skyrizi (risankizumab) and Rinvoq (upadacitinib), which treat a range of inflammatory and autoimmune conditions, including psoriasis, Crohn's disease, ulcerative colitis, and rheumatoid arthritis. The company also markets Botox and Juvederm in aesthetics, Vraylar and migraine treatments Ubrelvy and Qulipta in neuroscience, and Venclexta and Imbruvica in oncology.

AbbVie has spent recent years navigating the loss of exclusivity on Humira, once the world's best-selling drug, by building a diversified portfolio of newer medicines with long patent protection. Its competitive strengths include deep commercial scale across immunology, an expanding pipeline, and strong free-cash-flow generation that supports both dividend growth and targeted acquisitions.

Recent Developments Driving ABBV

AbbVie's third-quarter 2026 results, reported in late October, anchored the stock's recent performance. Total revenue increased about 10% to $17.4 billion, beating management's expectations, while adjusted EPS of $3.82 came in $0.07 above the guidance midpoint. Immunology led the way, with revenue approaching $9.2 billion on 16.6% operational growth. Skyrizi generated nearly $5.8 billion in sales, up 22.9% operationally, and Rinvoq grew 24.3% to $2.7 billion, more than compensating for Humira's 30.6% decline.

Management raised full-year revenue guidance by $200 million to approximately $67.8 billion and lifted adjusted EPS guidance to $13.95–$13.99, marking the third revenue increase of the year. The company also raised its quarterly dividend by 5.2% to $1.82 per share. Other developments included U.S. FDA approval of Skyrizi subcutaneous induction for Crohn's disease, the FDA approval of Juvmo for Parkinson's disease, and the completion of the Apogee Therapeutics acquisition, which adds the atopic dermatitis candidate zumilokibart to the pipeline.

Trending AI Robots

Tickeron's Trending AI Robots page is a curated showcase of the platform's top-performing and most relevant AI trading bots. While Tickeron offers hundreds of AI-driven trading bots that collectively trade thousands of tickers, only the strongest and most relevant strategies surface in this section. The bots vary widely in approach, trading timeframe, and performance metrics, ranging from short-term momentum models to longer-horizon trend-following systems. This diversity lets traders and investors browse strategies that align with their own risk tolerance and objectives. Exploring the Trending AI Robots page offers a way to observe how automated systems are positioned across the market.

2026 Outlook and What Investors Should Watch

Looking ahead, the central question for AbbVie is whether Skyrizi and Rinvoq can sustain their momentum through 2026 and into the next decade as competition in immunology intensifies. Investors will watch new indication launches, including Rinvoq's anticipated U.S. approvals for vitiligo and alopecia areata, and the ramp of Skyrizi's subcutaneous induction in Crohn's disease. In neuroscience, the early commercialization of Juvmo and continued growth from Vraylar and the oral CGRP migraine franchise will be key monitors.

Macro and policy risks remain relevant, including U.S. drug-pricing reform under the Inflation Reduction Act and payer reimbursement dynamics. The aesthetics segment, which has lagged amid softer consumer demand, and the oncology portfolio, pressured by Imbruvica's decline, will also be watched for signs of stabilization. AbbVie's strong free cash flow and pipeline progression provide visibility, but clinical trial outcomes and regulatory decisions carry inherent uncertainty.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

A.I.Advisor
a Summary for ABBV with price predictions
Nov 20, 2026

ABBV sees MACD Histogram crosses below signal line

ABBV saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 03, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 47 instances where the indicator turned negative. In 27 of the 47 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 57%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for ABBV moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In 18 of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at 42%.

The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ABBV as a result. In 36 of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 47%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABBV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 47%.

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a +0.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABBV advanced for three days, in 222 of 361 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.

ABBV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 217 of 349 cases where ABBV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 62%.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 1 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.

The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ABBV's P/B Ratio (-86.736) is very low in comparison to the industry average of (-1.421). ABBV has a moderately high P/E Ratio (82.291) as compared to the industry average of (21.700). Projected Growth (PEG Ratio) (0.544) is also within normal values, averaging (5.738). Dividend Yield (0.024) settles around the average of (0.038) among similar stocks. ABBV's P/S Ratio (7.231) is slightly higher than the industry average of (4.033).

The Tickeron Price Growth Rating for this company is 16 (best 1 - 100 worst), indicating outstanding price growth. ABBV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
published Dividends

ABBV paid dividends on November 16, 2026

ABBVIE ABBV Stock Dividends
А quarterly dividend of $1.73 per share was paid with a record date of November 16, 2026, and an ex-dividend date of October 15, 2026. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), AstraZeneca PLC (NYSE:AZN), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 215.99B. The market cap for tickers in the group ranges from 4.8K to 1.21T. LLY holds the highest valuation in this group at 1.21T. The lowest valued company is NEWG at 4.8K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was -13%. For the same Industry, the average monthly price growth was -10%, and the average quarterly price growth was -6%. OGN experienced the highest price growth at -0%, while SCLX experienced the biggest fall at -63%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was 59%. For the same stocks of the Industry, the average monthly volume growth was 59% and the average quarterly volume growth was 35%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 57
P/E Growth Rating: 36
Price Growth Rating: 50
SMR Rating: 61
Profit Risk Rating: 61
Seasonality Score: 13 (-100 ... +100)
View a ticker or compare two or three
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a research-based pharmaceutical company

Industry PharmaceuticalsMajor

Industry
Pharmaceuticals Major
Address
1 North Waukegan Road
Phone
+1 847 932-7900
Employees
57000
Web
https://www.abbvie.com
AbbVie (ABBV) Stock Analysis: Skyrizi and Rinvoq Power the Post-Humira Growth Era